The 26.7 Data Release provides data from human studies such as the Emory Healthy Brain Study, as well as updates to animal model studies including the MARMO-AD Study, which aims to generate, characterize, and validate the marmoset as a non-human primate model of aging.

Proper acknowledgment of data sources is not only mandatory for users of the AD Knowledge Portal, it also enhances the visibility of your work and elevates recognition of datasets used. All data use must be acknowledged with the following: the AD Knowledge Portal Acknowledgement Statement; and an Acknowledgement Statement specific to the study/dataset used, from the relevant Study page; and a Data Availability statement that includes a direct link to access relevant resources, known as a dataset DOI. For more information and pre-written acknowledgement statements, see Data Use & Acknowledgement.

Human

  • The Emory Healthy Brain Study

    The Emory Healthy Brain Study provides plasma proteomics datasets generated using a one-step ENRICHplus microbead-based enrichment workflow combined with data-independent acquisition mass spectrometry (DIA-MS) on the Orbitrap Astral platform. The dataset includes plasma samples from cognitively normal controls, individuals with mild cognitive impairment (MCI), and Alzheimer’s disease (AD) cases.

    • This release contains sample metadata as well as raw and processed protein abundance matrices for each dataset.

  • The AGMP-ADRC Study

    The Alzheimer Gut Microbiome Project (AGMP) Alzheimer’s Disease Research Center (ADCR) Study aims to define a role for the gut microbiome and metabolome in Alzheimer’s Disease through a multi-year longitudinal study with ~1000 participants, including those who are cognitively normal (at risk), have mild cognitive impairment (MCI), or have an AD diagnosis.

    • This release provides Baker Lipidomics and Metabolon data from 519 participants

Models

  • MARMO-AD Study

    The MARMO-AD Study aims to generate, characterize, and validate the marmoset as a non-human primate model of aging and Alzheimer’s Disease.

    • This release includes new raw RNASeq and WGS data from PBMCs and brain from multiple individuals, as well as updates to metadata files.

  • The Jax.IU.Pitt_TREM2.HSSvsR47H Study

    The Jax.IU.Pitt_TREM2.HSSvsR47H Study aims to provide initial characterization of novel mouse model Trem2em4Adiuj (Trem2R47HHSS). The Trem2em4Adiuj strain has a mutant mouse Trem2 gene consisting of an R47H point mutation along with 2 other silent mutations to create a “humanized” splice acceptor site in exon 2. This mouse model builds on Trem2em1Adiuj ( Trem2R47H, see Stock No. 027918) which has the R47H mutation but also expresses an unintended novel truncated splice variant due to a cryptic splice acceptor site in exon 2, causing reduced Trem2 expression. The cryptic slice site has been corrected in Trem2em4Adiuj and Trem2em4Adiuj expresses normal levels of transcript. Transcriptional profiles from brain tissue were compared to B6 control cohorts or Trem2R47H mice which contain the cryptic splice site in exon 2. We screened for molecular signatures associated with disease severity. Each strain was aged in cohorts to 4 months and 12 months of age, tested and sampled.